Chemistry:Epaminurad

From HandWiki

Epaminurad is an investigational new drug being developed by JW Pharmaceutical for the treatment of gout and hyperuricemia. It is a urate-lowering agent that selectively inhibits the human uric acid transporter 1 (hURAT1), promoting urate excretion.[1][2] As of 2024, epaminurad is undergoing Phase 3 clinical trials to evaluate its efficacy and safety compared to febuxostat in gout patients across multiple Asian countries.[3][1]

References

  1. ↑ 1.0 1.1 "JW Pharmaceutical's Epaminurad Shows Promise for Gout Treatment". 16 January 2024. https://www.businesskorea.co.kr/news/articleView.html?idxno=209603. 
  2. ↑ "Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors". Molecules (Basel, Switzerland) 28 (21): 7415. November 2023. doi:10.3390/molecules28217415. PMID 37959834. 
  3. ↑ "Emerging Drug Treatments for Gout". 9 February 2024. https://www.rheumatologyadvisor.com/features/fda-roundup-emerging-drug-treatments-for-gout/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Epaminurad&oldid=4031220"